Clinical Value of Combined Detection of Serum sTim-3 and Pepsinogen for Gastric Cancer Diagnosis

References

• Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-532861308
   PubMed Web of Science ®Google Scholar
• Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15(2):154–161. doi:10.1007/s10120-011-0091-821892754
   PubMed Web of Science ®Google Scholar
• He CZ, Zhang KH, Li Q, Liu XH, Hong Y, Lv NH. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol. 2013;13:87. doi:10.1186/1471-230X-13-8723672279
   PubMed Web of Science ®Google Scholar
• Huang ZB, Zhou X, Xu J, et al. Prognostic value of preoperative serum tumor markers in gastric cancer. World J Clin Oncol. 2014;5(2):170–176. doi:10.5306/wjco.v5.i2.17024829865
   PubMedGoogle Scholar
• Chen C, Chen Q, Zhao Q, Liu M, Guo J. Value of combined detection of serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the diagnosis of gastric cancer. Ann Clin Lab Sci. 2017;47(3):260–263.28667025
   PubMed Web of Science ®Google Scholar
• Yu J, Zheng W. An alternative method for screening gastric cancer based on serum levels of CEA, CA19-9, and CA72-4. J Gastrointest Cancer. 2018;49(1):57–62. doi:10.1007/s12029-016-9912-728028765
   PubMed Web of Science ®Google Scholar
• Miao J, Liu Y, Zhao G, et al. Feasibility of plasma-methylated SFRP2 for early detection of gastric cancer. Cancer Control. 2020;27(2):1073274820922559. doi:10.1177/107327482092255932379490
   PubMed Web of Science ®Google Scholar
• Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159. doi:10.3389/fonc.2019.0115931750248
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Waskito LA, Aftab H, et al. Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations. PLoS One. 2020;15(4):e0230064. doi:10.1371/journal.pone.023006432271765
   PubMed Web of Science ®Google Scholar
• Chiang TH, Chiu SY, Chen SL, et al. Serum pepsinogen as a predictor for gastric cancer death: a 16-year community-based cohort study. J Clin Gastroenterol. 2019;53(5):e186–e193. doi:10.1097/MCG.000000000000099229369241
   PubMed Web of Science ®Google Scholar
• Bang CS, Lee JJ, Baik GH. Diagnostic performance of serum pepsinogen assay for the prediction of atrophic gastritis and gastric neoplasms: protocol for a systematic review and meta-analysis. Medicine. 2019;98(4):e14240. doi:10.1097/MD.000000000001424030681610
   PubMed Web of Science ®Google Scholar
• Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Med J Islam Repub Iran. 2014;28:150.25695008
   PubMedGoogle Scholar
• Zeng W, Zhang S, Yang L, et al. Serum miR-101-3p combined with pepsinogen contributes to the early diagnosis of gastric cancer. BMC Med Genet. 2020;21(1):28. doi:10.1186/s12881-020-0967-832041551
   PubMed Web of Science ®Google Scholar
• Yu G, Wang GX, Wang HG, Mo FF, Tang BB. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. Neoplasma. 2019;66(4):637–640. doi:10.4149/neo_2018_180825N64731058531
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang H, Sun S, Sun S, Li L. The effects of Tim-3 activation on T-cells in gastric cancer progression. Oncol Lett. 2019;17(2):1461–1466.30675200
   PubMed Web of Science ®Google Scholar
• Gantuya B, Oyuntsetseg K, Bolor D, et al. Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area. Gastric Cancer. 2019;22(1):104–112. doi:10.1007/s10120-018-0844-829934751
   PubMed Web of Science ®Google Scholar
• Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. doi:10.1186/s12943-019-1091-231690319
   PubMed Web of Science ®Google Scholar
• Zhuang X, Zhang X, Xia X, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137(6):978–985. doi:10.1309/AJCP9Q6OVLVSHTMY22586058
   PubMed Web of Science ®Google Scholar
• Shang Y, Li Z, Li H, Xia H, Lin Z. TIM- 3 expression in human osteosarcoma: correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett. 2013;6(2):490–494. doi:10.3892/ol.2013.141024137353
   PubMed Web of Science ®Google Scholar
• Marcq E, Siozopoulou V, De Waele J, et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017;6(1):e1261241. doi:10.1080/2162402X.2016.126124128197385
   PubMed Web of Science ®Google Scholar
• Komohara Y, Morita T, Annan DA, et al. The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res. 2015;3(9):999–1007. doi:10.1158/2326-6066.CIR-14-015625783986
   PubMed Web of Science ®Google Scholar
• Yang M, Yu Q, Liu J, et al. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival. J Surg Oncol. 2015;112(4):430–435. doi:10.1002/jso.2401226265374
   PubMed Web of Science ®Google Scholar
• Chen M, Wang L, Wang Y, et al. Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy. J Clin Lab Anal. 2020;34(6):e23248.32077157
   PubMed Web of Science ®Google Scholar
• Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol. 1971;106(4):962–968.4396533
   PubMed Web of Science ®Google Scholar
• Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125(6):1636–1644. doi:10.1053/j.gastro.2003.08.03314724815
   PubMed Web of Science ®Google Scholar
• Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015;10(11):e0142080. doi:10.1371/journal.pone.014208026556485
   PubMed Web of Science ®Google Scholar
• Li P, He C, Sun L, Dong N, Yuan Y. Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease. BMC Clin Pathol. 2013;13(1):22. doi:10.1186/1472-6890-13-2224004680
   PubMedGoogle Scholar
• Nam SY, Jeon SW, Lee HS, Kwon YH, Park H, Choi JW. Long-term follow-up of pepsinogen I/II ratio after eradication of Helicobacter pylori in patients who underwent endoscopic mucosal resection for gastric cancer. Dig Liver Dis. 2017;49(5):500–506. doi:10.1016/j.dld.2016.12.01628057446
   PubMedGoogle Scholar
• Cho JH, Jeon SR, Kim HG, Jin SY, Park S. The serum pepsinogen levels for risk assessment of gastric neoplasms: new proposal from a case-control study in Korea. Medicine. 2017;96(29):e7603. doi:10.1097/MD.000000000000760328723806
   PubMed Web of Science ®Google Scholar
• Lorente S, Doiz O, Trinidad Serrano M, Castillo J, Lanas A. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut. 2002;50(1):13–18. doi:10.1136/gut.50.1.1311772960
   PubMed Web of Science ®Google Scholar
• Liu H, Zhi L, Duan N, Su P. Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients. FEBS Open Bio. 2016;6(8):807–815. doi:10.1002/2211-5463.12079
   PubMed Web of Science ®Google Scholar
• Lei L, Zhong XN, He ZY, Zhao C, Sun XJ. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice. Cell Biol Int. 2015;39(4):388–399. doi:10.1002/cbin.1041025492803
   PubMed Web of Science ®Google Scholar
• Solinas C, De Silva P, Bron D, Willard-Gallo K, Sangiolo D. Significance of TIM3 expression in cancer: from biology to the clinic. Semin Oncol. 2019;46(4–5):372–379. doi:10.1053/j.seminoncol.2019.08.00531733828
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7(2):e30676. doi:10.1371/journal.pone.003067622363469
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol. 2013;32(11):648–653. doi:10.1089/dna.2013.211624007284
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhou X, Huang X, et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One. 2013;8(1):e53834. doi:10.1371/journal.pone.005383423335978
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai P, Liang T, Wang L, Hu L. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(19):31705–31713. doi:10.18632/oncotarget.1595428423646
   PubMedGoogle Scholar
• Wang Z, Yin N, Zhang Z, Zhang Y, Zhang G, Chen W. Upregulation of T-cell immunoglobulin and mucin-domain Containing-3 (Tim-3) in monocytes/macrophages associates with gastric cancer progression. Immunol Investig. 2017;46(2):134–148. doi:10.1080/08820139.2016.122979027911104
   PubMed Web of Science ®Google Scholar
• Yegin ZA, Can F, Aydın Kaynar L, et al. Pre-transplant sTIM-3 levels may have a predictive impact on transplant outcome in acute leukemia patients. Hematology. 2020;25(1):125–133. doi:10.1080/16078454.2020.173809732153257
   PubMed Web of Science ®Google Scholar
• Geng H, Zhang GM, Li D, et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 2006;176(3):1411–1420. doi:10.4049/jimmunol.176.3.141116424168
   PubMed Web of Science ®Google Scholar
• Lu X, Yang L, Yao D, et al. Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer. Cell Immunol. 2017;313:43–51. doi:10.1016/j.cellimm.2017.01.00128110884
   PubMed Web of Science ®Google Scholar
• Naghavi-Alhosseini M, Tehrani M, Ajami A, et al. Tim-3 up-regulation in patients with gastric cancer and peptic ulcer disease. Asian Pac J Cancer Prev. 2017;18(3):765–770.28441784
   PubMedGoogle Scholar
• Wang Z, Zhu J, Gu H, et al. The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer. Immunol Investig. 2015;44(6):578–589. doi:10.3109/08820139.2015.105214526214042
   PubMed Web of Science ®Google Scholar
• Hu CC, Jeng WJ, Chen YC, et al. Memory regulatory T cells increase only in inflammatory phase of chronic hepatitis B infection and related to galectin-9/Tim-3 interaction. Sci Rep. 2017;7(1):15280. doi:10.1038/s41598-017-15527-x29127350
   PubMed Web of Science ®Google Scholar